Patents by Inventor Wenzi Pan

Wenzi Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Indoles and Their Use as Integrin Antagonists
    Publication number: 20070219233
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Application
    Filed: May 31, 2007
    Publication date: September 20, 2007
    Inventors: Tianbo Lu, Bruce Tomczuk, Louis LaFrance, Thomas Markotan, Juan Marugan Sanchez, Victor Marder, David U'Prichard, Beth Anaclerio, Zihong Guo, Wenzi Pan, Kristi Leonard
  • Substituted indoles and their use as integrin antagonists
    Patent number: 7241789
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: July 10, 2007
    Assignee: 3-Dimensional Pharmaceutical, Inc.
    Inventors: Tianbo Lu, Bruce E. Tomczuk, Louis V. LaFrance, Thomas P. Markotan, Juan J. Marugan Sanchez, Victor J. Marder, David C. U'Prichard, Beth M. Anaclerio, Zihong Guo, Wenzi Pan, Kristi A. Leonard
  • Substituted indoles and their use as integrin antagonists
    Publication number: 20050250771
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, , R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Application
    Filed: December 6, 2004
    Publication date: November 10, 2005
    Inventors: Tianbo Lu, Bruce Tomczuk, Louis LaFrance, Thomas Markotan, Juan Marugan Sanchez, Victor Marder, David U'Prichard, Beth Anaclerio, Zihong Guo, Wenzi Pan, Kristi Leonard
  • Substituted indoles and their use as integrin antagonists
    Publication number: 20050209225
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Application
    Filed: December 6, 2004
    Publication date: September 22, 2005
    Inventors: Tianbao Lu, Louis LaFrance, Bruce Tomczuk, Thomas Markotan, Juan Marugan Sanchez, Victor Marder, David U'Prichard, Beth Anaclerio, Zihong Guo, Wenzi Pan, Kristi Leonard
  • Substituted indoles and their use as integrin antagonists
    Patent number: 6855722
    Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: February 15, 2005
    Assignee: Dimensional Pharmaceuticals, Inc.
    Inventors: Tianbo Lu, Louis V. LaFrance, Thomas P. Markotan, Juan J. Marugan Sanchez, Victor J. Marder, David C. U'Prichard, Beth M. Anaclerio, Zihong Guo, Wenzi Pan, Kristi A. Leonard, Bruce E. Tomczuk